Skip to content
DataLookout
Menu

NCT05267626

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Sep 19, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 28 versions: 27 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
  2. Notable Eligibility criteria expanded, about 39 words
    • Primary endpoints: details revised at 1 of 2 entries
    • Study sites: 18 to 17
    • Secondary endpoints: details revised at 1 of 7 entries
  3. Notable Primary and study completion pushed from Jun 12, 2026 to Feb 28, 2027v27
  4. Minor Study sites: 17 to 18v25
  5. Minor Study sites: 16 to 17v24
Show 22 earlier versionsHide 22 earlier versions
  1. Minor Site details revised at 2 of 16 sitesv23
  2. Notable Primary and study completion dates pushed to Jun 12, 2026
    • Eligibility criteria expanded, about 110 words
    • Study sites: 13 to 16
    v22
  3. Notable Eligibility criteria shortened, about 63 words
    • Study description expanded, about 5 words
    v21
  4. Notable Eligibility criteria expanded, about 86 wordsv20 Show 4 more changesShow less
    • Interventions: AU-007 (Drug), Aldesleukin (Drug), Avelumab (Drug) to AU-007 (Drug), Aldesleukin (Drug), Avelumab (Drug), Nivolumab (Drug)
    • Secondary endpoints revised (7)
    • Study description shortened, about 11 words
    • Study arms: 4 to 5
  5. Minor Study description shortened, about 11 words
    • Study sites revised (13)
    v19
  6. Minor Study sites: 12 to 13v18
  7. Notable Eligibility criteria expanded, about 102 wordsv17 Show 6 more changesShow less
    • Primary endpoints revised (2)
    • Enrollment target: 136 to 159
    • Interventions: AU-007 (Drug), Aldesleukin (Drug) to AU-007 (Drug), Aldesleukin (Drug), Avelumab (Drug)
    • Secondary endpoints revised (7)
    • Study description expanded, about 18 words
    • Study arms: 3 to 4
  8. Notable Primary completion date: Oct 31, 2024 to Aug 31, 2025
    • Eligibility criteria expanded, about 2 words
    • Study sites: 10 to 12
    • Study completion date: Jan 31, 2025 to Sep 30, 2025
    v16
  9. Notable Enrollment target: 69 to 136
    • Primary completion date: Jul 30, 2024 to Oct 31, 2024
    • Study completion date: Oct 31, 2024 to Jan 31, 2025
    • Site details revised at 1 of 10 sites
    v15
  10. Minor Study sites: 9 to 10v14
  11. Minor Primary completion date: Jul 2024 to Jul 30, 2024v13
  12. Minor Study sites: 11 to 9v12
  13. Notable Primary completion date: Dec 2023 to Jul 2024
    • Study sites: 9 to 11
    • Study completion date: Mar 31, 2024 to Oct 31, 2024
    v11
  14. Minor Site details revised at 1 of 9 sitesv10
  15. Minor Study sites: 8 to 9v9
  16. Minor Study sites: 9 to 8v8
  17. Notable Eligibility criteria expanded, about 13 wordsv7
  18. Minor Study sites: 5 to 9v6
  19. Minor Study sites: 3 to 5v5
  20. Notable Eligibility criteria expanded, about 2 words
    • Enrollment target: 60 to 69
    • Study sites: 4 to 3
    • Start date changed from estimate of Apr 2022 to Apr 4, 2022
    v4
  21. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 3 to 4
    • Start date: Mar 31, 2022 to Apr 2022
    v3
  22. Notable Enrollment target: 126 to 60v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Evaluate the safety and tolerability of AU-007
Timeframe: Day 1 thru end of treatment (EOT) visit (28 days after last dose)
Establish the maximum tolerated dose (MTD) and/or RP2D
Timeframe: Day 1 thru EOT visit (28 days after last dose)

Secondary (7)

Magnitude of PK changes in the blood after dosing determined by area under the curve (AUC) of AU-007
Magnitude of PK changes in the blood after dosing determined by maximum concentration (Cmax) of AU-007
Magnitude of PK changes in the blood after dosing determined by time of maximum concentration (Tmax)
Magnitude of PK changes in the blood after dosing determined by Half-life (T1/2) of AU-007
Magnitude of cytokine changes in the blood after dosing
Show 2 moreShow less
Magnitude of immunogenicity after dosing with AU-007 alone or in combination with aldesleukin, AU-007 in combination with aldesleukin and avelumab or nivolumab
Evaluate the preliminary anti-tumor activity of AU-007 alone, in combination with aldesleukin, in combination with aldesleukin and avelumab, and AU-007 plus aldesleukin with nivolumab in patients with unresectable locally advanced or metastatic cancer

Arms and interventions

AU-007 MonotherapyExperimental

AU-007 (Q2w) administered as a monotherapy sequential ascending doses with each Dose Escalation Cohort (Complete; no longer enrolling)

AU-007 combined with a single dose of aldesleukinExperimental

AU-007 (Q2w) administered in combination with a single dose of aldesleukin with the initial AU-007 dose.

AU-007 combined with aldesleukin given concomitantlyExperimental

AU-007 administered in combination with aldesleukin, both administered Q2w (Complete; no longer enrolling)

AU-007 plus aldesleukin in combination avelumabExperimental

AU-007 and avelumab administered Q2w with a single dose of aldesleukin with the initial AU-007 dose

AU-007 plus aldesleukin in combination with nivolumabExperimental

AU-007 (Q2w) administered in combination with a single dose of aldesleukin with the initial AU-007 dose. Nivolumab will be administered Q4w.

Drugs: AU-007, Aldesleukin, Avelumab, Nivolumab

Sites

17 sites in 2 countries

United States 10, Australia 7